330 related articles for article (PubMed ID: 33676197)
1. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Kim HJ; Nakashima I; Viswanathan S; Wang KC; Shang S; Miller L; Yountz M; Wingerchuk DM; Pittock SJ; Levy M; Berthele A; Totolyan N; Palace J; Barnett MH; Fujihara K;
Mult Scler Relat Disord; 2021 May; 50():102849. PubMed ID: 33676197
[TBL] [Abstract][Full Text] [Related]
2. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM; Fujihara K; Palace J; Berthele A; Levy M; Kim HJ; Nakashima I; Oreja-Guevara C; Wang KC; Miller L; Shang S; Sabatella G; Yountz M; Pittock SJ;
Ann Neurol; 2021 Jun; 89(6):1088-1098. PubMed ID: 33586143
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ; Fujihara K; Palace J; Berthele A; Kim HJ; Oreja-Guevara C; Nakashima I; Levy M; Shang S; Yountz M; Miller L; Armstrong R; Wingerchuk DM;
Mult Scler; 2022 Mar; 28(3):480-486. PubMed ID: 34498507
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Frampton JE
Drugs; 2020 May; 80(7):719-727. PubMed ID: 32266705
[TBL] [Abstract][Full Text] [Related]
10. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
[TBL] [Abstract][Full Text] [Related]
11. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.
Sen S; Tuncer A; Terzi M; Bunul SD; Ozen-Acar P; Altunrende B; Ozakbas S; Tutuncu M; Uygunoglu U; Akman-Demir G; Karabudak R; Efendi H; Siva A
Mult Scler Relat Disord; 2023 Nov; 79():104949. PubMed ID: 37678131
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
[TBL] [Abstract][Full Text] [Related]
13. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ; Barnett M; Bennett JL; Berthele A; de Sèze J; Levy M; Nakashima I; Oreja-Guevara C; Palace J; Paul F; Pozzilli C; Yountz M; Allen K; Mashhoon Y; Kim HJ
Ann Neurol; 2023 Jun; 93(6):1053-1068. PubMed ID: 36866852
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
[TBL] [Abstract][Full Text] [Related]
15. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
[TBL] [Abstract][Full Text] [Related]
16. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K
Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314
[TBL] [Abstract][Full Text] [Related]
17. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
[TBL] [Abstract][Full Text] [Related]
18. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
[TBL] [Abstract][Full Text] [Related]
19. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan.
Nakashima I; Nakahara J; Yokote H; Manabe Y; Okamura K; Hasegawa K; Fujihara K
Ther Adv Neurol Disord; 2023; 16():17562864231181177. PubMed ID: 37441104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
